Dr. Juliet Vento

Dr. Juliet Vento

Senior Medical Director, Medical

Subject Expert
About

Dr. Juliet Vento is the Senior Medical Director at Quotient Sciences Miami. As the medical lead for our Miami clinical research unit, Dr. Vento provides strategic medical oversight across all early‑phase clinical programs, while supporting protocol development, investigator training, study conduct and formulation design. Her work includes overseeing first‑in‑human, SAD/MAD, PK/PD, bioavailability, bioequivalence, drug–drug interaction, food‑effect, tQT and special‑population studies.

Prior to her current role, Dr. Vento held senior medical leadership positions within pharmaceutical and clinical research organizations, including Medical Director at Teva Pharmaceuticals and Principal Investigator roles at multiple research centers in South Florida. Across these positions, she has contributed to the execution of more than 57 clinical trials across a wide range of therapeutic areas, collaborating closely with sponsors, CROs, and regulatory bodies to optimize trial design and execution while maintaining strict adherence to GCP and safety standards.

Dr. Vento earned her Doctor of Medicine degree from the University of Illinois at Chicago and completed her Internal Medicine residency at Mount Sinai Medical Center in Miami Beach in 2016. Her early scientific training includes research programs at Mayo Medical School and Duke University School of Medicine, complemented by a Bachelor of Science in Biomedical Engineering from Florida International University. She maintains active Florida medical licensure, DEA registration, and Internal Medicine Board Certification through the American Board of Internal Medicine.

Quotient Sciences Logo
Clinical Pharmacology, Regulatory Affairs

Phase I/Clinical Pharmacology Info Sheet

Read More

Latest news from Quotient Sciences

More News
News & Announcements, Articles & Publications, Artificial Intelligence Andy Lewis on AI‑Enabled Formulation Design and Faster Speed to Clinic By: Andy Lewis
Read More
News & Announcements, Articles & Publications, Early Drug Development, Artificial Intelligence AI's Role in Fast-tracking Early Drug Development; Our ground breaking alliance with Intrepid Labs By: Andy Lewis
Read More
News & Announcements, Articles & Publications, Artificial Intelligence Building Trust in AI‑Enabled Formulation: Insights from Quotient Sciences and Intrepid Labs By: Andy Lewis
Read More